Search Results - "Taylor, Khalilah E"

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors by Edwards, A Cole, Stalnecker, Clint A, Jean Morales, Alexis, Taylor, Khalilah E, Klomp, Jennifer E, Klomp, Jeffrey A, Waters, Andrew M, Sudhakar, Niranjan, Hallin, Jill, Tang, Tracy T, Olson, Peter, Post, Leonard, Christensen, James G, Cox, Adrienne D, Der, Channing J

“…Primary/intrinsic and treatment-induced acquired resistance limit the initial response rate to and long-term efficacy of direct inhibitors of the KRASG12C…”
Get full text

Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer by Klomp, Jennifer E, Diehl, J Nathaniel, Klomp, Jeffrey A, Edwards, A Cole, Yang, Runying, Morales, Alexis J, Taylor, Khalilah E, Drizyte-Miller, Kristina, Bryant, Kirsten L, Schaefer, Antje, Johnson, Jared L, Huntsman, Emily M, Yaron, Tomer M, Pierobon, Mariaelena, Baldelli, Elisa, Prevatte, Alex W, Barker, Natalie K, Herring, Laura E, Petricoin, 3rd, Emanuel F, Graves, Lee M, Cantley, Lewis C, Cox, Adrienne D, Der, Channing J, Stalnecker, Clint A

“…To delineate the mechanisms by which the ERK1 and ERK2 mitogen-activated protein kinases support mutant KRAS-driven cancer growth, we determined the…”
Get full text

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers by Klomp, Jeffrey A, Klomp, Jennifer E, Stalnecker, Clint A, Bryant, Kirsten L, Edwards, A Cole, Drizyte-Miller, Kristina, Hibshman, Priya S, Diehl, J Nathaniel, Lee, Ye S, Morales, Alexis J, Taylor, Khalilah E, Peng, Sen, Tran, Nhan L, Herring, Laura E, Prevatte, Alex W, Barker, Natalie K, Hover, Laura D, Hallin, Jill, Chowdhury, Saikat, Coker, Oluwadara, Lee, Hey Min, Goodwin, Craig M, Gautam, Prson, Olson, Peter, Christensen, James G, Shen, John P, Kopetz, Scott, Graves, Lee M, Lim, Kian-Huat, Wang-Gillam, Andrea, Wennerberg, Krister, Cox, Adrienne D, Der, Channing J

“…How the oncogene drives cancer growth remains poorly understood. Therefore, we established a systemwide portrait of KRAS- and extracellular signal-regulated…”
Get full text

Abstract IA-06: Elucidation of metabolic resistance mechanisms to RAS inhibition by DeLiberty, Jonathan M., Robb, Ryan, Roach, Mallory K., Ackermann, Sarah E., Yang, Runying, Pieper, Noah L., Taylor, Khalilah E., Bang, Scott, Baldelli, Elisa, Petricoin, Emanuel F., Morris, John P., Stalnecker, Clint A., Bryant, Kirsten L.

“…Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS- and autophagy-dependent growth. We previously determined that concurrent inhibition…”
Get full text

Abstract C026: Concurrent inhibition of the RAS ERK-MAPK pathway and PIKfyve as a therapeutic strategy for pancreatic cancer by DeLiberty, Jonathan M, Roach, Mallory K, Stalnecker, Clint A, Robb, Ryan, Schechter, Elyse G, Pieper, Noah L, Yang, Runying, Bang, Scott, Taylor, Khalilah E, Drizyte-Miller, Kristina, Morris, John P, Der, Channing J, Cox, Adrienne D, Bryant, Kirsten L

“…Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized clinically by poor survival and mechanistically by KRAS- and autophagy-dependent growth. We…”
Get full text

Abstract B009: TEAD inhibition overcomes YAP1/TAZ-driven resistance to RAS inhibitors in KRASG12C-mutant cancers by Edwards, Alexander C., Stalnecker, Clint A., Morales, Alexis J., Taylor, Khalilah E., Hallin, Jill, Olson, Peter, Tang, Tracy T., Engstrom, Lars, Post, Leonard, Christensen, James G., Cox, Adrienne D., Der, Channing J.

“…Abstract Activated mutants of KRAS comprise the major oncogenic drivers in lung (LAC), colorectal (CRC), and pancreatic ductal (PDAC) adenocarcinoma. Recent…”
Get full text

Abstract B034: Determination of KRAS- and ERK-regulated phosphoproteomes in KRAS-mutant cancers by Klomp, Jennifer E., Klomp, Jeff A., Diehl, Nathaniel J., Edwards, Cole A., Drizyte-Miller, Kristina, Hibshman, Priya S., Yang, Runying, Morales, Alexis J., Taylor, Khalilah E., Pierobon, Mariaelena, Petricoin, Emanuel F., Jared, Johnson L., Huntsman, Emily M., Yaron, Tomer M., Vähä-Koskela, Markus, Herring, Laura E., Prevatte, Alex W., Barker, Natalie K., Graves, Lee M., Krister, Wennerberg, Cantley, Lewis C., Christensen, James G., Cox, Adrienne D., Der, Channing J., Stalnecker, Clint A.

“…Abstract Direct inhibitors of mutationally activated KRAS are currently under intense preclinical and clinical development, with one KRASG12C mutant-selective…”
Get full text